SIĞIR PAPİLLOMATOZİSİNDE SAĞALTIM AMACIYLA UYGULANAN İVERMEKTİNİN SERUM TNF-α VE IL-6 DÜZEYLERİNE ETKİSİNİN BELİRLENMESİ

Bu çalışmanın amacı, sığır papillomlarının tedavisinde kullanılan ivermektinin, serum TNF-α ve IL-6 üzerine olan etkisinin belirlenmesidir. Bu çalışmaya, klinik olarak papillomatozis olduğu belirlenen, yaşları 15-20 aylar arasında değişen, 9 hasta sığır (4’ü erkek Montofon, 3’ü dişi Montofon 1’i dişi Yerli kara, 1’i dişi Holştayn) dahil edildi. Tüm sığırlardan kan örnekleri alındıktan sonra, 0,2 mg/kg dozunda ivermektin, deri altı yol ile uygulandı. İlk uygulamayı takiben 7, 22 ve 52. günlerde kan alındıktan sonra klinik kontrolleri yapıldı. Çalışmaya dahil edilen hayvanlardan 4’ünde (1 Holştayn, 3 Montofon) papillomlarda %90-100 oranında gerileme belirlenirken, 2 hayvanda (2 Montofon) % 70-80 gerileme, diğer hayvanlarda (1 Yerli kara, 2 Montofon) ise herhangi bir gerileme olmadığı belirlendi. Alınan serum örneklerinde TNF-α ve IL-6 düzeylerinin ivermektin uygulamasını takiben 7. günde arttığı, 22 ve 52. günlerde ise giderek azaldığı, ancak bu değişimin istatistiksel olarak önemli olmadığı belirlendi (P>0,05). Sonuç olarak; sığır papillomatozisinde tedavi amacıyla uygulanan ivermektinin hayvanlarda iyileşmeye etkisi olduğu, serum TNF-α ve IL-6 düzeylerinde değişimler oluşturduğu belirlendi. Bu sonuçlara göre ivermektinin etki şekliyle ilgili daha kapsamlı çalışmalar yapılması gerektiği kanısına varıldı.

The Effect of Ivermectin on Serum Tnf-Α And Il-6 Levels In Bovine Papillomatosis

This study aimed to evaluate the effects of the ivermectin used in the treatment of bovine papillomatosis on serum TNF-α and IL-6. Nine cattle with different ages (15-20 months old), breed (4 male Brown Swiss, 3 female Brown Swiss, 1 female Native Black, 1 female Holstein with clinically bovine papillomatosis were included. After taking blood samples from all animals, ivermectin at a dose of 0.2 mg/kg was administered subcutaneously as a single dose. On the 7, 22 and 52nd days after the first application, blood sampling and the monitoring of the animals were repeated. Four animals (1 Brown Swiss and 3 Brown Swiss) and two animals (2 Brown Swiss) regressed nearly 90-100 % and 70-80 %, respectively while in other animals (1 Native Black and 2 Brown Swiss) no remission was observed during the observation period. Serum TNF-α and IL-6 levels were determined to have increased on the 7th day and decreased on the 22nd and 52nd days following the administration, but no statistically significance (p>0.05). It was concluded that ivermectin might be effective on clinically recovery and serum TNF-α and IL-6 levels. More comprehensive future studies on higher numbers of animals are warranted.

___

  • 1. Jelinek F, Tachezy R. Cutaneous papillomatosis in cattle. J Comp Path 2005; 132:70-81.
  • 2. Lancaster WD, Olson C. Animal papillomaviruses. Microbiol Rev 1982; 46:191-207.
  • 3. Nicholls PK, Stanley MA. The immunology of animal papillomavirüses. Vet Immun Immunopathol 2000; 73:101-127.
  • 4. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
  • 5. Camplo MS. Bovine Papillomavirus: Old system, new lessons? In: Camplo MS (eds), Papillomavirus Biology: From Natural History to Vaccine and Beyond. Academic Press, England 2006; pp 1-34.
  • 6. Bajrić A, Jevtić S, Ožegović T, Dugalic N. Autohaemotherapy of bovine papillomatosis. Vet Yugoslavia 1983; 32:79-83.
  • 7. Biricik HS, Keskin O, Çimtay I, Baba ZF. Sığır papillomatozisinin tedavisinde otolog aşı ve otohemoterapi uygulamalarının karsılaştırılması. Turk J Vet Anim Sci 2003; 27:703-707.
  • 8. Börkü MK, Atalay O, Kibar M, Cam Y, Atasever A. Ivermectin is an effective treatment for bovine cutaneous papillomatosis. Res Vet Sci 2007; 83:360- 363.
  • 9. Kırmızıgül AH, Gökçe E, Sözmen M, Yıldırım Y, Beytut E. İvermektin’in sığır deri papillomatozisinde tedavi etkinliği. Kafkas Univ Vet Fak Derg 2010; 16:627-631.
  • 10. Silva LAF, Jayme VS, Oliveira MAB, et al. Cutaneous pedicle implant of the papilloma and autohaemotherapy in the treatment of bovine papillomatosis. Vet Noticias 1998; 4:83-88.
  • 11. Courtney CH, Roberson EL. Avermectin. In: Adams HR (eds), Veterinary Pharmacology and Therapeutics, Iowa State University Pres, Ames, Iowa 1995; pp 920.
  • 12. Knab J, Darge K, Buttner DW. Immunohistological studies on macrophages in lymph nodes of onchocerciasis patients after treatment with ivermectin. Trop Med Int Health 1997; 2:1156- 1169.
  • 13. Uhlir J. Effect of ivermectin on the development of serum antibody activity in rabbits infested with Psoroptes cuniculi (Acari: Psoroptidae). Folia Parasitol (Praha) 1991; 38:79-82.
  • 14. Diker KS. İmmunoloji. Medisan Yayınevi, Ankara 2005; ss 85-95.
  • 15. Dalmath T. Arthropod transmission of rabbit papillomatosis. J Exptl Med 1958; 108:9-20.
  • 16. Desrochers A, St-Jean G, Kennedy GA. Congenital cutaneous papillomatosis in a one-year-old Holstein. Can Vet J 1994; 35:646-647.
  • 17. Santos EUD, SilvaMRA, Pontes NE, et al. Detection of different bovine papillomavirus types and coinfection in bloodstream of cattle. Transbound Emerg Dis 2016; 63:103-108.
  • 18. Brandt S, Haralambus R, Schoster A, Kirnbauer R, Stanek C. Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines, J Gen Virol 2008; 89:1390-1395.
  • 19. Lesnik F, Bires J, Suli J, et al. Autovaccination and metabolic profiles at bovine papillomatosis. Slovak Vet J 1999; 24:290-294.
  • 20. Breitburd F, Salmon J, Orth G. The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Clin Dermatol 1997; 15:237-247.
  • 21. Nicholls PK, Klaunberg BA, Moore RA, et al Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 1999; 265:365-374.
  • 22. Mercan U. Toksikolojide serbest radikallerin önemi. YYU Vet Fak Derg 2004; 15:91-96.
  • 23. Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPSinduced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res 2008; 57:524-529.
  • 24. Rosenkrans C, Nihsen M, Flores R, Schrick N. Effects of forage cultivar and anthelmintic on steer responses to immune challenge. Proc Western Sec Am Soc Anim Sci 2005; 56:243-245.
  • 25. Spiers DE, Evans TJ, Rottinghaus GE. Interaction between thermal stress and fescue toxicosis: animal models and new perspectives. In: Roberts CA, West CP, Spiers DE (eds), Neotyphodium in cool-season grasses. Blackwell Publishing, Oxford 2008; pp 248.
  • 26. Rosenkrans CF, Bedingfield T, Piper E. Physiological responses of steers to ingestion of endophyteinfected hay, ivermectin treatment, and immune challenge. 4th International Neotyphodium/Grass Interactions Symposium, Universitat Paderborn, Soest 2001; pp 255-260.
  • 27. Sajid MS, Iqbal Z, Muhammad G, Iqbal MU. Immunomodulatory effect of various antiparasitics: A review. Parasitology 2006; 132:301- 313.
Sağlık Bilimleri Dergisi-Cover
  • ISSN: 1018-3655
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 1993
  • Yayıncı: Prof.Dr. Aykut ÖZDARENDELİ